#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC

Kyle LaHucik

Senior Reporter

CHICAGO — In its “first time on a bigger stage” at this weekend’s ASCO conference, Cullinan Oncology thinks it has the data to “distinguish itself” …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

#AS­CO22: With me­di­an dura­bil­i­ty da­ta, Cul­li­nan aims to 'dis­tin­guish it­self' from Takeda's Exkiv­i­ty and J&J's Ry­bre­vant in ex­on 20 NSCLC

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials